NYSE - Nasdaq Real Time Price • USD
Novo Nordisk A/S (NVO)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 8 | 8 |
| Avg. Estimate | 0.73 | 0.76 | 3.35 | 4.03 |
| Low Estimate | 0.68 | 0.71 | 3.16 | 3.54 |
| High Estimate | 0.78 | 0.82 | 3.58 | 4.77 |
| Year Ago EPS | 0.64 | 0.63 | 2.66 | 3.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 7 | 7 |
| Avg. Estimate | 9.02B | 9.53B | 41.32B | 49.25B |
| Low Estimate | 8.69B | 9.26B | 39.51B | 44.01B |
| High Estimate | 9.41B | 9.68B | 43.62B | 53.21B |
| Year Ago Sales | 7.59B | 7.97B | 33.13B | 41.32B |
| Sales Growth (year/est) | 18.90% | 19.60% | 24.70% | 19.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.63 | 0.65 | 0.73 | 0.64 |
| EPS Actual | 0.64 | 0.63 | 0.73 | 0.7 |
| Difference | 0.01 | -0.02 | 0 | 0.06 |
| Surprise % | 1.60% | -3.10% | 0.00% | 9.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.73 | 0.76 | 3.35 | 4.03 |
| 7 Days Ago | 0.72 | 0.75 | 3.33 | 3.99 |
| 30 Days Ago | 0.75 | 0.77 | 3.35 | 3.95 |
| 60 Days Ago | 0.78 | 0.79 | 3.31 | 3.93 |
| 90 Days Ago | 0.82 | 0.79 | 3.2 | 3.77 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | NVO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 14.10% | -- | -- | 2.60% |
| Next Qtr. | 20.60% | -- | -- | 13.40% |
| Current Year | 25.90% | -- | -- | 5.20% |
| Next Year | 20.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 2.80% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 19.23% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Initiated | BMO Capital: Outperform | 4/12/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/20/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/8/2024 |
Related Tickers
VKTX Viking Therapeutics, Inc.
68.86
+5.82%
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
MRNA Moderna, Inc.
106.18
-2.45%
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
REGN Regeneron Pharmaceuticals, Inc.
890.68
-1.75%
ALT Altimmune, Inc.
7.20
+1.69%
NVAX Novavax, Inc.
3.9500
-4.82%
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
IBRX ImmunityBio, Inc.
5.11
+6.02%